{"title":"FDA advisers vote unanimously in favor of OTC birth control pills","link":"https://arstechnica.com/?p=1938251","date":1683748840000,"content":"<div>\n<figure>\n  <img src=\"https://cdn.arstechnica.net/wp-content/uploads/2023/05/Opill-800x600.png\" alt=\"FDA advisers vote unanimously in favor of OTC birth control pills\" />\n      <p><a href=\"https://cdn.arstechnica.net/wp-content/uploads/2023/05/Opill.png\">Enlarge</a> (credit: Perrigo)</p>  </figure>\n\n\n\n\n\n\n<div><a name=\"page-1\"></a></div>\n<p>A panel of independent medical experts for the Food and Drug Administration voted unanimously on Wednesday in favor of allowing the hormonal birth control pill Opill (norgestrel) to be sold over the counter rather than by prescription.</p>\n<p>The 17-0 vote by the panel came after a two-day meeting in which they reviewed data and analysis from the pill's maker, Laboratoire HRA Pharma, and FDA scientists, as well as public comments on the potential switch.</p>\n<p>Opill is a once-a-day pill containing only progestin. It was first approved in 1973 and has proven remarkably safe in the five decades since then, proving safer than combination hormone pills that have risks of blood clots. Experts estimate Opill is about 93 percent effective at preventing pregnancy in real-life use, higher than the <a href=\"https://www.guttmacher.org/fact-sheet/contraceptive-effectiveness-united-states\">real-life efficacy</a> of other easily accessible birth-control methods, such as condoms (around 87 percent).</p></div><p><a href=\"https://arstechnica.com/?p=1938251#p3\">Read 11 remaining paragraphs</a> | <a href=\"https://arstechnica.com/?p=1938251&amp;comments=1\">Comments</a></p>","author":"Beth Mole","siteTitle":"Ars Technica","siteHash":"5b0ddf6e8923e49262a7894cfd77962733e43fbcc565a103b48373820b310636","entryHash":"b9f3523def6665a3d4b120c93b3d416d4a5951827d877b017d7dc96ff3cb5cf2","category":"Tech"}